Nephros(NEPH)
icon
搜索文档
Nephros(NEPH) - 2023 Q1 - Quarterly Report
2023-05-11 04:07
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: _______ to _______ Commission File Number: 001-32288 NEPHROS, INC. (Exact name of registrant as specified in its charter) DELAWARE 13-3971809 (State or other ...
Nephros(NEPH) - 2022 Q4 - Annual Report
2023-03-24 05:05
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32288 NEPHROS, INC. (Exact name of registrant specified in its charter) Delaware 13-3971809 (State or Other Jurisdiction of (I.R.S. Employer Incorpor ...
Nephros(NEPH) - 2022 Q4 - Earnings Call Transcript
2023-03-09 11:28
Nephros, Inc. (NASDAQ:NEPH) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ET Company Participants Kirin Smith - PCG Advisory Andrew Astor - President and CEO Conference Call Participants Anthony Vendetti - Maxim Group Joseph Schuler - JAS Investors Operator Good afternoon, and welcome to the Nephros Inc. Fourth Quarter 2022 Financial Results Conference Call. [Operator Instructions] Please note, this event is being recorded. I would now like to turn the conference over to Kirin Smith, Investor Relat ...
Nephros (NEPH) Investor Presentation - Slideshow
2019-04-03 03:10
1 Nephros, Inc. OTCQB: NEPH Corporate Presentation Q1 2019 www.nephros.com Safe Harbor Statement Certain statements in this management presentation constitute "forward-looking statements". Such statements include statements regarding the efficacy and intended use of our technologies under development, the timelines and strategy for bringing such products to market and the availability of funding sources for continued development of such products and other statements that are not historical facts, including ...